| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 11 | 2022 | 500 | 3.470 |
Why?
|
| Healthcare Disparities | 11 | 2021 | 201 | 2.840 |
Why?
|
| Sex Factors | 22 | 2022 | 643 | 2.550 |
Why?
|
| Antihypertensive Agents | 8 | 2021 | 161 | 2.410 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 5 | 2021 | 5 | 2.360 |
Why?
|
| Cardiopulmonary Resuscitation | 5 | 2021 | 15 | 2.170 |
Why?
|
| Multimodal Imaging | 7 | 2024 | 7 | 2.030 |
Why?
|
| Myocardial Infarction | 11 | 2017 | 238 | 1.800 |
Why?
|
| African Americans | 7 | 2021 | 472 | 1.740 |
Why?
|
| Exercise Test | 5 | 2017 | 44 | 1.720 |
Why?
|
| Medication Adherence | 5 | 2022 | 244 | 1.700 |
Why?
|
| Humans | 67 | 2024 | 17611 | 1.480 |
Why?
|
| Registries | 20 | 2022 | 471 | 1.470 |
Why?
|
| Cardiovascular Diseases | 7 | 2024 | 598 | 1.450 |
Why?
|
| Cardiology | 7 | 2024 | 30 | 1.440 |
Why?
|
| Heart Failure | 7 | 2020 | 396 | 1.420 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 318 | 1.340 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2019 | 3 | 1.280 |
Why?
|
| Male | 46 | 2022 | 10008 | 1.280 |
Why?
|
| Female | 50 | 2022 | 12608 | 1.230 |
Why?
|
| Blood Pressure | 5 | 2019 | 298 | 1.230 |
Why?
|
| Racism | 4 | 2021 | 19 | 1.170 |
Why?
|
| Risk Assessment | 7 | 2022 | 1097 | 1.120 |
Why?
|
| United States | 33 | 2024 | 3956 | 1.110 |
Why?
|
| Middle Aged | 32 | 2022 | 7911 | 1.030 |
Why?
|
| Patient Selection | 3 | 2019 | 190 | 1.010 |
Why?
|
| Coronary Disease | 3 | 2011 | 181 | 0.980 |
Why?
|
| Heart Diseases | 3 | 2019 | 77 | 0.950 |
Why?
|
| Defibrillators, Implantable | 6 | 2019 | 32 | 0.940 |
Why?
|
| Social Values | 2 | 2021 | 14 | 0.830 |
Why?
|
| Aged | 26 | 2022 | 6095 | 0.820 |
Why?
|
| Follow-Up Studies | 13 | 2022 | 1210 | 0.790 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 86 | 0.770 |
Why?
|
| Myocardial Ischemia | 3 | 2022 | 24 | 0.770 |
Why?
|
| Cardiologists | 2 | 2018 | 8 | 0.750 |
Why?
|
| Heart Valve Diseases | 2 | 2017 | 20 | 0.740 |
Why?
|
| Risk Factors | 15 | 2022 | 3325 | 0.740 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 34 | 0.740 |
Why?
|
| Attitude to Health | 1 | 2021 | 164 | 0.720 |
Why?
|
| Coronary Artery Disease | 5 | 2022 | 134 | 0.720 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2015 | 35 | 0.700 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2018 | 43 | 0.690 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 330 | 0.690 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2017 | 22 | 0.690 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2020 | 27 | 0.690 |
Why?
|
| Anticoagulants | 2 | 2018 | 127 | 0.680 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 37 | 0.680 |
Why?
|
| Sleep | 1 | 2020 | 58 | 0.670 |
Why?
|
| Primary Prevention | 4 | 2015 | 73 | 0.670 |
Why?
|
| Disease Management | 2 | 2019 | 135 | 0.670 |
Why?
|
| Patient Discharge | 4 | 2017 | 154 | 0.670 |
Why?
|
| Aged, 80 and over | 12 | 2021 | 1900 | 0.650 |
Why?
|
| Public Opinion | 1 | 2019 | 6 | 0.650 |
Why?
|
| Ultrasonography | 1 | 2019 | 35 | 0.650 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 19 | 0.650 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 170 | 0.640 |
Why?
|
| Lung | 1 | 2019 | 62 | 0.630 |
Why?
|
| Hemoglobins | 1 | 2017 | 39 | 0.590 |
Why?
|
| Anemia | 1 | 2017 | 32 | 0.590 |
Why?
|
| Thromboembolism | 1 | 2017 | 32 | 0.580 |
Why?
|
| Guideline Adherence | 1 | 2018 | 155 | 0.560 |
Why?
|
| Warfarin | 1 | 2017 | 74 | 0.560 |
Why?
|
| Stroke | 3 | 2020 | 311 | 0.540 |
Why?
|
| Ambulatory Care | 1 | 2018 | 244 | 0.530 |
Why?
|
| Societies, Medical | 5 | 2024 | 74 | 0.530 |
Why?
|
| Quality of Health Care | 1 | 2018 | 326 | 0.510 |
Why?
|
| Retrospective Studies | 13 | 2020 | 2447 | 0.500 |
Why?
|
| American Heart Association | 5 | 2020 | 49 | 0.500 |
Why?
|
| Adult | 16 | 2022 | 7598 | 0.490 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 171 | 0.480 |
Why?
|
| Sex Distribution | 5 | 2020 | 190 | 0.460 |
Why?
|
| Health Status Disparities | 3 | 2021 | 146 | 0.440 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 2 | 0.440 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 3 | 0.440 |
Why?
|
| Postoperative Hemorrhage | 1 | 2013 | 8 | 0.430 |
Why?
|
| Drug Resistance | 1 | 2012 | 30 | 0.410 |
Why?
|
| Prospective Studies | 7 | 2019 | 1267 | 0.400 |
Why?
|
| Cardiac Catheterization | 1 | 2011 | 8 | 0.380 |
Why?
|
| Treatment Outcome | 10 | 2017 | 1259 | 0.380 |
Why?
|
| Electrocardiography | 1 | 2011 | 42 | 0.380 |
Why?
|
| Young Adult | 8 | 2022 | 2427 | 0.380 |
Why?
|
| Incidence | 7 | 2022 | 1255 | 0.360 |
Why?
|
| Patient Preference | 1 | 2011 | 48 | 0.360 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 568 | 0.350 |
Why?
|
| Resuscitation Orders | 2 | 2020 | 3 | 0.340 |
Why?
|
| Aspirin | 2 | 2017 | 63 | 0.330 |
Why?
|
| Prognosis | 6 | 2019 | 606 | 0.320 |
Why?
|
| Heart Arrest | 2 | 2020 | 34 | 0.320 |
Why?
|
| Coronary Angiography | 1 | 2008 | 21 | 0.310 |
Why?
|
| Colorado | 3 | 2021 | 163 | 0.310 |
Why?
|
| Thoracic Surgery | 2 | 2017 | 2 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 375 | 0.290 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 105 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 205 | 0.280 |
Why?
|
| Echocardiography | 4 | 2020 | 32 | 0.270 |
Why?
|
| Time Factors | 6 | 2018 | 1086 | 0.260 |
Why?
|
| Secondary Prevention | 2 | 2017 | 47 | 0.250 |
Why?
|
| Peptide Fragments | 2 | 2017 | 27 | 0.250 |
Why?
|
| Sex Characteristics | 5 | 2022 | 69 | 0.240 |
Why?
|
| Hospital Mortality | 4 | 2018 | 145 | 0.240 |
Why?
|
| Odds Ratio | 5 | 2017 | 671 | 0.220 |
Why?
|
| Survival Rate | 5 | 2020 | 260 | 0.220 |
Why?
|
| Women's Health | 2 | 2016 | 200 | 0.210 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 351 | 0.210 |
Why?
|
| Cohort Studies | 6 | 2020 | 2570 | 0.210 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 114 | 0.200 |
Why?
|
| Writing | 1 | 2021 | 11 | 0.200 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 20 | 0.200 |
Why?
|
| Single-Blind Method | 1 | 2021 | 44 | 0.200 |
Why?
|
| Professional-Patient Relations | 1 | 2021 | 47 | 0.190 |
Why?
|
| Indians, North American | 1 | 2021 | 49 | 0.190 |
Why?
|
| Atherosclerosis | 1 | 2022 | 51 | 0.190 |
Why?
|
| Patient Readmission | 2 | 2020 | 163 | 0.190 |
Why?
|
| Logistic Models | 4 | 2012 | 926 | 0.180 |
Why?
|
| Heart Defects, Congenital | 1 | 2020 | 37 | 0.180 |
Why?
|
| Self Report | 1 | 2022 | 251 | 0.180 |
Why?
|
| Telephone | 1 | 2021 | 161 | 0.180 |
Why?
|
| Congresses as Topic | 1 | 2020 | 13 | 0.180 |
Why?
|
| Biomarkers | 2 | 2017 | 301 | 0.170 |
Why?
|
| Electric Countershock | 1 | 2019 | 16 | 0.170 |
Why?
|
| Poverty | 1 | 2020 | 166 | 0.170 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2019 | 6 | 0.170 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 28 | 0.160 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 8 | 0.160 |
Why?
|
| Communication | 2 | 2018 | 194 | 0.160 |
Why?
|
| Prevalence | 2 | 2019 | 884 | 0.160 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2019 | 2 | 0.160 |
Why?
|
| Sexuality | 1 | 2019 | 11 | 0.160 |
Why?
|
| Sex Offenses | 1 | 2019 | 8 | 0.160 |
Why?
|
| Postmenopause | 1 | 2020 | 241 | 0.160 |
Why?
|
| Ventricular Function | 1 | 2018 | 1 | 0.160 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 2 | 0.160 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 1 | 0.160 |
Why?
|
| Clinical Audit | 1 | 2018 | 3 | 0.160 |
Why?
|
| Heart Failure, Systolic | 1 | 2018 | 4 | 0.160 |
Why?
|
| Residence Characteristics | 1 | 2020 | 248 | 0.150 |
Why?
|
| Anesthesiology | 1 | 2017 | 2 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2019 | 230 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 3 | 0.150 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 3 | 0.150 |
Why?
|
| Medicare | 4 | 2022 | 202 | 0.150 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2017 | 10 | 0.150 |
Why?
|
| F Factor | 1 | 2017 | 1 | 0.150 |
Why?
|
| Mortality | 2 | 2008 | 117 | 0.150 |
Why?
|
| Ezetimibe | 1 | 2017 | 4 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 45 | 0.150 |
Why?
|
| Critical Care | 1 | 2018 | 71 | 0.150 |
Why?
|
| Simvastatin | 1 | 2017 | 11 | 0.150 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 14 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2019 | 167 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2017 | 85 | 0.140 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 18 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2017 | 62 | 0.140 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 154 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 27 | 0.140 |
Why?
|
| Waiting Lists | 1 | 2017 | 12 | 0.140 |
Why?
|
| Heart Transplantation | 1 | 2017 | 11 | 0.140 |
Why?
|
| Health Personnel | 1 | 2018 | 124 | 0.140 |
Why?
|
| Depression | 1 | 2021 | 502 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 88 | 0.140 |
Why?
|
| Blood Pressure Determination | 2 | 2014 | 54 | 0.140 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 42 | 0.140 |
Why?
|
| Veterans | 1 | 2017 | 141 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 129 | 0.130 |
Why?
|
| Medicaid | 1 | 2017 | 186 | 0.130 |
Why?
|
| Angiography | 3 | 2020 | 12 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 14 | 0.120 |
Why?
|
| Pregnancy | 1 | 2020 | 1494 | 0.120 |
Why?
|
| Age Factors | 4 | 2022 | 917 | 0.120 |
Why?
|
| Hospitals | 1 | 2014 | 80 | 0.110 |
Why?
|
| Hirudins | 1 | 2013 | 1 | 0.110 |
Why?
|
| Antithrombins | 1 | 2013 | 4 | 0.110 |
Why?
|
| Stroke Volume | 1 | 2013 | 100 | 0.100 |
Why?
|
| Diuretics | 1 | 2012 | 17 | 0.100 |
Why?
|
| Eligibility Determination | 2 | 2009 | 12 | 0.100 |
Why?
|
| Adolescent | 5 | 2020 | 3651 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 69 | 0.090 |
Why?
|
| Ethnic Groups | 1 | 2014 | 485 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 710 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2008 | 709 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2008 | 27 | 0.080 |
Why?
|
| Heart Rate | 1 | 2008 | 40 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2009 | 102 | 0.080 |
Why?
|
| Poisson Distribution | 1 | 2008 | 88 | 0.080 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2017 | 2 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2014 | 766 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 297 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 185 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 748 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2024 | 16 | 0.060 |
Why?
|
| Exercise | 1 | 2008 | 489 | 0.060 |
Why?
|
| Hospitalization | 2 | 2020 | 797 | 0.060 |
Why?
|
| Cholesterol | 1 | 2022 | 106 | 0.050 |
Why?
|
| Alaska | 1 | 2021 | 16 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2022 | 108 | 0.050 |
Why?
|
| Perception | 1 | 2021 | 58 | 0.050 |
Why?
|
| Knowledge | 1 | 2001 | 3 | 0.050 |
Why?
|
| Teaching Materials | 1 | 2001 | 4 | 0.050 |
Why?
|
| Information Services | 1 | 2001 | 16 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 5 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2000 | 4 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2000 | 7 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2000 | 23 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 49 | 0.040 |
Why?
|
| Age Distribution | 1 | 2020 | 246 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 91 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 41 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2018 | 4 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 66 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 103 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2018 | 6 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2018 | 12 | 0.040 |
Why?
|
| Minority Health | 1 | 2018 | 4 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 42 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 110 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 381 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2017 | 24 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1322 | 0.040 |
Why?
|
| Asian Americans | 1 | 2018 | 176 | 0.040 |
Why?
|
| Veterans Health | 1 | 2017 | 21 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2017 | 215 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2018 | 104 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 24 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2017 | 44 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2018 | 254 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 130 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 127 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 187 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 231 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 212 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2015 | 9 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2017 | 106 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 1309 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 35 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 181 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 594 | 0.030 |
Why?
|
| Radial Artery | 1 | 2014 | 2 | 0.030 |
Why?
|
| Dementia | 1 | 2015 | 106 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 179 | 0.030 |
Why?
|
| Child | 1 | 2020 | 2474 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 197 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 119 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 218 | 0.030 |
Why?
|
| Insulin | 1 | 2014 | 205 | 0.030 |
Why?
|
| Glycated Hemoglobin A | 1 | 2014 | 216 | 0.030 |
Why?
|
| California | 1 | 2019 | 2284 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 630 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 487 | 0.020 |
Why?
|
| Obstetrics | 1 | 2011 | 22 | 0.020 |
Why?
|
| Gynecology | 1 | 2011 | 20 | 0.020 |
Why?
|
| Neoplasms | 1 | 2015 | 438 | 0.020 |
Why?
|
| Obesity | 1 | 2017 | 837 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 531 | 0.020 |
Why?
|
| Cause of Death | 1 | 2008 | 181 | 0.020 |
Why?
|
| Consumer Advocacy | 1 | 2001 | 4 | 0.010 |
Why?
|
| Insurance Benefits | 1 | 2001 | 14 | 0.010 |
Why?
|
| Education | 1 | 2001 | 17 | 0.010 |
Why?
|
| Filgrastim | 1 | 2000 | 1 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2000 | 21 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 2000 | 19 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2000 | 155 | 0.010 |
Why?
|
| Data Collection | 1 | 2001 | 256 | 0.010 |
Why?
|